Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
7.7650
+0.1250 (1.64%)
Avadel Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for patients with sleep disorders, specifically targeting conditions like narcolepsy and obstructive sleep apnea
The company leverages its proprietary drug delivery technology to create novel formulations designed to improve patient outcomes and enhance medication adherence. Avadel aims to address unmet medical needs through its advanced therapies while also pursuing strategic partnerships and collaborations to expand its product offerings and reach in the pharmaceutical market.

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.
Via MarketBeat · February 19, 2025

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Via MarketBeat · January 20, 2025

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
Via Benzinga · January 17, 2024

Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY.
Via Benzinga · January 9, 2025

Via Benzinga · December 19, 2024

Via Benzinga · October 31, 2024

AVDL stock results show that Avadel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.
Via Investor's Business Daily · August 6, 2024

Via Benzinga · December 20, 2023

AVDL stock results show that Avadel Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024

Via Benzinga · March 28, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · March 5, 2024

Avadel Pharmaceuticals plc (NASDAQAVDL) reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday.
Via Benzinga · March 5, 2024

Via Benzinga · March 4, 2024

Companies Reporting Before The Bell • Sohu.com (NASDAQSOHU) is estimated to report earnings for its fourth quarter.
Via Benzinga · March 4, 2024

Shares of RxSight, Inc. (NASDAQRXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
Via Benzinga · January 8, 2024

Avadel Pharmaceuticals plc (NASDAQAVDL) recognized $7.0 million in net product revenue for Q3.
Via Benzinga · November 8, 2023

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via Benzinga · November 8, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session.
Via Benzinga · August 11, 2023